Sprint Bioscience AB (FRA:5JA1) Total Liabilities: €1.18 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5JA1 Sprint Bioscience AB FRA:5JA1
32 GF Score
Price €0.30
GF Value €0.19
! 1 Warning Sign
View Full Analysis

What is Sprint Bioscience AB Total Liabilities?

Sprint Bioscience AB FRA:5JA1 -3.54% 32 Total Liabilities is €1.18 Mil as of Mar. 2026. GuruFocus rates FRA:5JA1 with a GF Score™ of 32/100 and a GF Value™ of €0.19. The stock has 1 warning sign investors should review.

Sprint Bioscience AB's Total Liabilities for the quarter that ended in Mar. 2026 was €1.18 Mil.

Sprint Bioscience AB's quarterly Total Liabilities increased from Sep. 2025 (€1.40 Mil) to Dec. 2025 (€1.61 Mil) but then declined from Dec. 2025 (€1.61 Mil) to Mar. 2026 (€1.18 Mil).

Sprint Bioscience AB's annual Total Liabilities declined from Dec. 2023 (€3.09 Mil) to Dec. 2024 (€2.85 Mil) and declined from Dec. 2024 (€2.85 Mil) to Dec. 2025 (€1.61 Mil).

Sprint Bioscience AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Sprint Bioscience AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB Total Liabilities Chart

Sprint Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.84 3.09 2.85 1.61

Sprint Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.76 2.21 1.40 1.61 1.18
FRA:5JA1
32GF Score
Sprint Bioscience AB FRA:5JA1
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sprint Bioscience AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sprint Bioscience AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.607+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.61

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=12.558-10.951
=1.61

Sprint Bioscience AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.178+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.18

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=11.045-9.867
=1.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €1.18 Mil mean?
Sprint Bioscience AB (FRA:5JA1) has a Total Liabilities of €1.18 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sprint Bioscience AB and its competitors.
Is Sprint Bioscience AB's Total Liabilities too high?
Sprint Bioscience AB's current Total Liabilities is €1.18 Mil. Overall, Sprint Bioscience AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Total Liabilities compare to VRTX and REGN?
Sprint Bioscience AB's Total Liabilities of €1.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sprint Bioscience AB and its competitors. Sprint Bioscience AB's current Total Liabilities is €1.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Sprint Bioscience AB (FRA:5JA1) has a current Total Liabilities of €1.18 Mil. The stock's GF Value™ is €0.19, compared to a current price of €0.30 — trading 57.9% above its estimated fair value. The current Total Liabilities is €1.18 Mil. Sprint Bioscience AB's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Sprint Bioscience AB (FRA:5JA1), the current Total Liabilities is €1.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sprint Bioscience AB (FRA:5JA1) Overvalued in 2026?

Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued. The current stock price of €0.30 is trading 57.9% above its estimated GF Value™ of €0.19.

Key valuation signals for FRA:5JA1:

  • Total Liabilities: €1.18 Mil
  • GF Value™: €0.19 vs. price of €0.30 (57.9% above fair value)
  • GF Score™: 32/100 with 1 warning sign

No single metric tells the full story. See the FRA:5JA1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sprint Bioscience AB Business Description

Other Exchanges SPRINT:Sweden
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score

Get the complete analysis for FRA:5JA1

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price
€0.19
GF Value